Rabih Said

National Institutes of Health — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index569citations56works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(12), Cancer Treatment and Pharmacology(7), Lung Cancer Treatments and Mutations(6), Heat shock proteins research(5), Advanced Breast Cancer Therapies(5)

Publications56 total

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids
SLAS DISCOVERY·2025· 6 citedOpen Access
Trial in Progress: CTEP 10492, A Phase 1/1b Study of the AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinoma
International Journal of Radiation Oncology*Biology*Physics·2024
CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma.
Journal of Clinical Oncology·2024· 2 cited
A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449).
Journal of Clinical Oncology·2024
Trial in Progress: A Phase 1/1a Study of Venetoclax, Ixazomib and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis PA160 (#328)
2024
Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
Cancer Research·2024
Abstract PO1-06-14: Preliminary results of a phase I dose escalation study of eribulin in combination with copanlisib in patients with metastatic triple negative breast cancer (TNBC)
Cancer Research·2024· 1 cited
Abstract CT042: NCI10217: Phase Ib biomarker-driven tumor-agnostic combination (Combo) trial of copanlisib (Copa) and olaparib (Ola) in molecularly-selected patients (pts) with advanced cancers with PIK3CA hotspot, PTEN and DNA damage response (DDR) mutations
Cancer Research·2024· 1 cited
Abstract C045: Combinations of PI3K inhibitors with targeted oncology agents in multicellular spheroid models
Molecular Cancer Therapeutics·2023
Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase II Study
Blood·2023
701P NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Annals of Oncology·2023· 1 citedOpen Access
Data from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
Data from Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
2023Open Access
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
Journal of Clinical Oncology·2022· 4 cited
Aplastic anemia secondary to dual cancer immunotherapies a physician nightmare: case report and literature review
Allergy Asthma and Clinical Immunology·2021· 9 citedOpen Access
Aplastic Anemia Secondary to Dual Cancer Immunotherapies A Physician Nightmare: Case Report and Literature Review
2021· 1 citedOpen Access
Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience
Cancers·2020· 28 citedOpen Access
Circulating tumor DNA analysis in the era of precision oncology
Oncotarget·2020· 51 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Apostolia M. Tsimberidou(27), David S. Hong(17), Aung Naing(17), Siqing Fu(15), Razelle Kurzrock(15), Gerald S. Falchook(13), Sarina A. Piha‐Paul(12), Jennifer J. Wheler(10), Filip Jankú(8), Kenneth R. Hess(8), Ralph Zinner(6), Gerald R. Galluppi(4), Naveen Dakappagari(4), Chris Storgard(4), Lee S. Rosen(4), Gary A. Palmer(4), Brittney Haas(3), Jingqin Luo(3), Gerburg M. Wulf(3), X. Cynthia(3)